Monitoring

Follow-up of positive cases of lymphatic filariasis after Transmission Assessment Survey (TAS) 2 and TAS 3 in Burkina Faso

Identify the sampling strategy for tracking positive cases after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of active transmission, while saving program resources

Countries: Burkina Faso

Whole genome sequencing of ocular Chlamydia trachomatis in Amhara region, Ethiopia, an area with persistent hyperendemic trachoma.

This study will address the characteristics of the ocular chlamydia trachomatis population structures within Amhara, a setting which has experienced repeated rounds of antibiotic for trachoma, and whether those circulating populations are different than known sequenced strains.

Countries: Ethiopia
Diseases: Trachoma

Understanding areas of increased trachoma risk (hotspots) through the implementation of a post validation trachoma surveillance strategy

To determine if there is evidence of on-going or recent transmission in the “hotspot” communities of increased risk two years after they were identified during the pre-validation surveys (clinical, antibody and infection data).

Countries: Ghana
Diseases: Trachoma

Coverage Evaluation Survey and Supervisor's Coverage Tool Implementation in Kenya for Triple Drug Therapy

Coverage Evaluation Survey

Is coverage, or a combination of coverage and systematic non-compliance, more effective than a diagnostic tool at predicting when it is safe to stop triple drug therapy?

Supervisor's Coverage Tool

Is the use of the SCT during IDA feasible to implement at the sub-county scale and does it lead to increased coverage?

Countries: Kenya

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt

What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Egypt

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Kenya

Lymphatic Filariasis Positive-Case Follow-up After TAS 2 in Haiti

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Haiti

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Samoa

District Mapping Onchocerciasis and Lymphatic Filariasis in Ethiopia

To assess the programmatic feasibility of and determine the most appropriate age group and sampling strategy for an oncho mapping survey for ivermectin-naïve areas

Countries: Ethiopia

Lymphatic filariasis positive-case follow-up after TAS 2 or TAS 3 in Philippines

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Philippines

Pages